Learn About Systemic Sclerosis (SSc)
Riverside Physician Services Inc
Chase Correia is a Rheumatologist in Hampton, Virginia. Dr. Correia is rated as an Elite provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Necrotizing Vasculitis. Dr. Correia is currently accepting new patients.
Johns Hopkins Bayview Medical Center
Laura Hummers is an Associate Professor of Medicine in the Division of Rheumatology. She graduated from the University of Rochester School of Medicine and trained in internal medicine at Thomas Jefferson University. She then pursued her rheumatology fellowship at Johns Hopkins University and has since been on the faculty working at the Johns Hopkins Scleroderma Center since 2003 where she has been Co-Director of the Center. She received her ScM degree through the Graduate Training Program in Clinical Investigation from the Bloomberg School of Public Health in 2010. Dr. Hummers also serves as Clinical Director for the Division of Rheumatology. Dr. Hummers actively participates in a number of clinical trials and clinical investigations at the Scleroderma Center and has a particular interest in predictors of outcomes in scleroderma. She actively manages a large patient practice focused exclusively on scleroderma and related conditions at Johns Hopkins and actively helps to manage the Johns Hopkins Scleroderma Center longitudinal database. She also has specific expertise in other scleroderma-like conditions such as scleromyxedema, scleredema and eosinophilic fasciitis. Dr. Hummers is rated as an Elite provider by MediFind in the treatment of Systemic Sclerosis (SSc). Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Eosinophilic Fasciitis, and Scleroma.
Cleveland Clinic Main Campus
Soumya Chatterjee is a Rheumatologist in Cleveland, Ohio. Dr. Chatterjee is rated as an Elite provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleredema, and Raynaud Phenomenon.
Summary: The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Summary: This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and sprea...